Sarah joined the Therapeutic Vaccine Research Program at Kirby Institute in 2018 after more than 10 years working in Clinical Haematology Research. Sarah currently manages a research project investigating whether DNA incorporation of azacitidine derivatives in mononuclear cells is higher following 21 days of oral azacitidine than following 7 days of Vidaza® in a 28 day treatment cycle.